Medically reviewed by Drugs.com. Last updated on Oct 3, 2019.
Applies to the following strengths: 20 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Myeloma
80 mg orally on Day 1 and 3 of each week until disease progression or unacceptable toxicity
-The recommended starting dosage of dexamethasone is 20 mg orally with each dose of this drug Day 1 and 3 of each week
-For additional information regarding the administration of dexamethasone, refer to its prescribing information.
-Consider IV hydration for patients at risk of dehydration.
-Provide prophylactic concomitant treatment with a 5-HT3 antagonist and/or other anti-nausea agents prior to and during therapy.
Use: In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
-Starting dose: 80 mg on Day 1 and 3 of each week (160 mg total per week)
-First reduction: 100 mg once a week
-Second reduction: 80 mg once a week
-Third reduction: 60 mg once a week
-Fourth reduction: Discontinue therapy
DOSE REDUCTION FOR ADVERSE REACTIONS:
HEMATOLOGIC ADVERSE REACTIONS:
-Platelet count 25,000 to less than 75,000/mcL: For any occurrence reduce the dose by 1 dose level.
-Platelet count 25,000 to less than 75,000/mcL with concurrent bleeding: For any occurrence interrupt therapy and restart at 1 dose level lower after bleeding has resolved.
-Platelet count less than 25,000/mcL: For any occurrence interrupt therapy; monitor until platelet count returns to 50,000/mcL; restart at 1 dose level lower.
-Absolute neutrophil count 0.5 to 1 x 10(9)/L without fever: For any occurrence reduce the dose by 1 dose level.
-Absolute neutrophil count less than 0.5 x 10(9)/L OR febrile neutropenia: For any occurrence interrupt therapy; monitor until neutrophil count returns to 1 x 10(9)/L; restart therapy at 1 dose level lower.
-Hemoglobin less than 8 g/dL: For any occurrence reduce the dose by 1 dose level; administer blood transfusions and/or other treatments per clinical guidelines.
-Life-threatening consequences (urgent intervention indicated): For any occurrence interrupt therapy; monitor hemoglobin until levels return to 8 g/dL or higher; restart therapy at 1 dose level lower; administer blood transfusions and/or other treatments per clinical guidelines.
NONHEMATOLOGIC ADVERSE REACTIONS:
-Sodium level 130 mmol/L or less: For any occurrence interrupt therapy and provide supportive care; monitor until sodium levels return to 130 mmol/L or higher; restart therapy at 1 dose level lower.
-Grade 2 lasting longer than 7 days OR Grade 3: For any occurrence interrupt therapy; monitor until fatigue resolves to Grade 1 or baseline; restart therapy at 1 dose level lower.
NAUSEA AND VOMITING:
-Grade 1 or 2 nausea (oral intake decreased without significant weight loss, dehydration, or malnutrition) OR Grade 1 or 2 vomiting (5 or fewer episodes per day): For any occurrence continue therapy and initiate additional anti-nausea medications.
-Grade 3 nausea (inadequate oral caloric or fluid intake) OR Grade 3 or higher vomiting (6 or more episodes per day): For any occurrence interrupt therapy; monitor until nausea or vomiting has resolved to Grade 2 or lower or baseline; initiate additional anti-nausea medications; restart therapy at 1 dose level lower.
-Grade 2 (increase of 4 to 6 stools per day over baseline): For first occurrence continue therapy and institute supportive care; for second occurrence reduce dose by 1 dose level and institute supportive care.
-Grade 3 or higher (increase of 7 stools or more per day over baseline; hospitalization indicated): For any occurrence interrupt therapy and institute supportive care; monitor until diarrhea resolves to Grade 2 or lower; restart therapy at 1 dose level lower.
WEIGHT LOSS AND ANOREXIA:
-Weight loss of 10% to less than 20% OR anorexia associated with significant weight loss or malnutrition: For any occurrence interrupt therapy and institute supportive care; monitor until weight returns to more than 90% of baseline weight; restart therapy at 1 dose level lower.
OTHER NONHEMATOLOGIC ADVERSE REACTIONS:
-Grade 3 or 4 (life-threatening): For any occurrence interrupt therapy; monitor until resolved to Grade 2 or lower; restart therapy at 1 dose level lower.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-This drug should be taken at the same time each day.
-Swallow tablets whole with water; do not break, chew, crush, or divide the tablet.
-If a dose is missed or delayed, take the next dose at the next regularly scheduled time.
-If a patient vomits a dose, the patient should not repeat the dose and should take the next dose on the next regularly scheduled day.
-Store at or below 30C (86F).
-Monitor complete blood count (CBC), standard blood chemistry, and body weight at baseline and during therapy; monitor more frequently during the first 2 months.
-Maintain adequate fluid and caloric intake throughout therapy.
More about selinexor
- Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- Drug class: miscellaneous antineoplastics
Other brands: Xpovio